This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers

Stocks in this article: MACK

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast, ovarian, gastric and bladder, will be presented at the ESMO 2012 Congress (European Society for Medical Oncology ), Sept. 28Oct. 2 in Vienna, Austria. The medicines are some of the first therapies developed using Merrimack's proprietary scientific approach – Network Biology – focusing not on gene expression but on underlying cancer signals that trigger tumor growth.

"At Merrimack Pharmaceuticals, we believe the key to finding new treatment options for cancer is to start closer to the source of the problem – with signals in the cancer cell that turn specific processes on and off, triggering tumor growth and drug resistance," said Robert J. Mulroy, President and Chief Executive Officer, Merrimack Pharmaceuticals. "By charting and modeling these molecular pathways and signals, we can identify the most sensitive points from which to attack the cancer and then develop medicines and companion diagnostics to disrupt or slow tumor growth."

Therapy and Poster Overview:

  • MM-121 is a fully human monoclonal antibody that binds to ErbB3, a protein central to the development of drug resistance and tumor growth in numerous cancers, including ovarian, breast and lung tumors. It is designed to block the signal that allows ErbB3 to bind with other proteins and trigger cell growth and drug resistance.
    • A Phase 1 Study of the Anti-ErbB3 Antibody MM-121 in Combination with Weekly Paclitaxel in Patients with Advanced Gynecological and Breast Cancers (Abstract #: 974PD)
      • Presentation: Gynecological Cancers, Sunday, Sept. 30, 2012, 1:00PM2:00PM CET, Hall G
  • MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell receptor. MM-111 is designed to uniquely address the tumor growth and survival signaling promoted by the ErbB2, ErbB3 and heregulin signaling complex.
    • A Phase 1 Study of MM-111; a Bispecific HER2/HER3 Antibody Fusion Protein, Combined with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors (Abstract #: 496P)
      • Poster Session: Poster Presentation III, Monday, Oct. 1, 2012, 1:00PM2:00PM CET, Hall XL

About Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs